康哲药业(00867.HK) 公布,集团自主研发的创新药CMS-D017胶囊获中国国家药品监督管理局临床试验批准,同意集团在中国健康参与者中开展评价CMS-D017安全性、耐受性、药代动力学和药效动力学特征的临床试验。CMS-D017是一种新型选择性补体因子B小分子抑制剂,通过靶向抑制补体因子B,阻止补体旁路途径的异常活化,减低膜攻击复合物对靶组织和器官的损伤,缓解补体失调相关疾病的进展。(de/...
Source Link康哲药业(00867.HK) 公布,集团自主研发的创新药CMS-D017胶囊获中国国家药品监督管理局临床试验批准,同意集团在中国健康参与者中开展评价CMS-D017安全性、耐受性、药代动力学和药效动力学特征的临床试验。CMS-D017是一种新型选择性补体因子B小分子抑制剂,通过靶向抑制补体因子B,阻止补体旁路途径的异常活化,减低膜攻击复合物对靶组织和器官的损伤,缓解补体失调相关疾病的进展。(de/...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.